Active	Status	Sponsor type	Region	Phase	Filter
3 Active 2 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Klapper, Jack A
NEUP11-7, NCT05267535: Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease	Active, not recruiting	2/3	225	Canada, US	Piromelatine 20 mg, Neu-P11, Placebo	Neurim Pharmaceuticals Ltd., Syneos Health	Alzheimer's Disease	06/25	06/25
LIFT-AD, NCT04488419: ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease	Completed	2/3	554	US	ATH-1017, Placebo	Athira Pharma	Alzheimer Disease, Dementia of Alzheimer Type	07/24	07/24
Weir, Liam
ALTITUDE-AD, NCT06335173: A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants with Early Alzheimer's Disease	Active, not recruiting	2	540	Europe, Canada, US	sabirnetug, Placebo	Acumen Pharmaceuticals	Alzheimer Disease	10/26	10/26